Daewoong Pharmaceutical "Nabota Reduces Postherpetic Neuralgia Pain"

[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical's botulinum toxin product 'Nabota' has been proven to have an effect in reducing postherpetic neuralgia pain.

Daewoong Pharmaceutical announced on the 9th that these research results were published in a Vietnamese medical journal. Nabota, which obtained product approval in Vietnam in 2017, is sold locally under the brand name 'Byutem.'

This study was conducted by Professor Dang Bich Diep of the Vietnam National Dermatology Hospital, targeting local Vietnamese patients.

The researchers randomly assigned 30 patients suffering from postherpetic neuralgia into two groups and compared the effects of Nabota administration with those of lidocaine, a local anesthetic, administered to the control group.

The Nabota group received injections diluted to 2.5U/0.1㎖, with 0.1㎖ injected at 1?2 cm intervals per pain site, while the lidocaine group received 0.1㎖ of lidocaine per pain site.

After the injections, the degree of pain improvement was evaluated using the VAS pain scale, and the progress was observed for up to 4 months post-injection. Patients' sleep quality and satisfaction were also assessed.

The study results showed that both groups experienced a statistically significant reduction in pain one week after the injection. However, while the Nabota group maintained continuous pain reduction effects up to 4 months post-injection, the lidocaine group experienced a worsening of pain one month after the injection.

In terms of sleep quality, the Nabota group showed statistically significant improvement from one week after the injection, with effects lasting up to 4 months. Additionally, patient satisfaction was higher in the Nabota group compared to the lidocaine group. No serious adverse drug reactions were reported.

Park Sung-soo, Head of Nabota Business Division at Daewoong Pharmaceutical, said, “This study was led directly by local researchers in a country where Nabota has been launched,” adding, “It served as an opportunity to demonstrate Nabota’s position as a global botulinum toxin brand.”